| X-linked agammaglobulinemia
Hizentra vs Octagam 5%
Side-by-side clinical, coverage, and cost comparison for x-linked agammaglobulinemia.Deep comparison between: Hizentra vs Octagam Immune Globulin (Human) with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOctagam Immune Globulin (Human) has a higher rate of injection site reactions vs Hizentra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Octagam Immune Globulin (Human) but not Hizentra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hizentra
Octagam Immune Globulin (Human)
At A Glance
SC injection
Daily to every 2 weeks
Immune globulin
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
Indications
- Primary immune deficiency disorder
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Wiskott-Aldrich Syndrome
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Primary immune deficiency disorder, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency Individualized SC dose administered daily to every 2 weeks; when switching from IGIV, initial weekly dose = prior IGIV dose (g) divided by weeks between doses, multiplied by 1.37.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 0.2 g/kg (1 mL/kg) SC per week in 1-2 infusion sessions over 1-2 consecutive days; may increase to 0.4 g/kg per week if symptoms worsen on the lower dose.
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 300-600 mg/kg IV every 3-4 weeks; adjust dose over time to achieve desired trough levels and clinical response.
Measles Exposure 400 mg/kg IV as soon as possible and within 6 days of exposure; increase to at least 530 mg/kg every 3-4 weeks if patient is at risk of future measles exposure.
Contraindications
- History of anaphylactic or severe systemic reaction to human immune globulin or inactive ingredients of HIZENTRA, including polysorbate 80
- Hyperprolinemia Type I or II (HIZENTRA contains L-proline as stabilizer)
- IgA-deficiency with antibodies against IgA and a history of hypersensitivity
- Acute severe hypersensitivity reaction to human immunoglobulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity
- Acute hypersensitivity reaction to corn (product contains maltose derived from corn)
Adverse Reactions
Most common (>=5%) Local infusion-site reactions (swelling, redness, heat, pain, hematoma, itching), headache, diarrhea, fatigue, back pain, nausea, pain in extremity, cough, upper respiratory tract infection, rash, pruritus, vomiting, abdominal pain, migraine, arthralgia, pain, fall, nasopharyngitis
Postmarketing Allergic-anaphylactic reactions (swollen face or tongue, pharyngeal edema, pyrexia, chills, dizziness, hypertension, malaise, tachycardia, flushing), chest discomfort, dyspnea, tremor, burning sensation, infusion site ulcer, infusion site necrosis
Most common (>=5%) headache, nausea
Serious anaphylactic reactions, thromboembolic events, aseptic meningitis, hemolytic anemia
Postmarketing leukopenia, hemolytic anemia, anaphylactic shock, angioedema, cerebrovascular accident, myocardial infarction, pulmonary embolism, renal failure acute, transfusion-related acute lung injury
Pharmacology
Immune Globulin Subcutaneous (Human), 20% Liquid that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Intravenous immunoglobulin G preparation that supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacteria and their toxins; restores abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hizentra
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Octagam Immune Globulin (Human)
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (7/12) · Qty limit (0/12)
UnitedHealthcare
Hizentra
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (1/8)
Octagam Immune Globulin (Human)
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Hizentra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Octagam Immune Globulin (Human)
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hizentra.
No savings programs available for Octagam Immune Globulin (Human).
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HizentraView full Hizentra profile
Octagam Immune Globulin (Human)View full Octagam Immune Globulin (Human) profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.